Difference between revisions of "Marotta LL, et al. J. Clin. Invest. (2011) cited as Ref 332 in DOI: 10.1038/s41392-020-0110-5 (Q9595)"
Jump to navigation
Jump to search
(Created claim: Publication Date (P100): 2011, #quickstatements; #temporary_batch_1590002823654) |
(Created claim: Page(s) (P105): 2723-2735, #quickstatements; #temporary_batch_1590074839150) |
||
| (3 intermediate revisions by the same user not shown) | |||
| Property / Published In Name String | |||
| + | J. Clin. Invest. | ||
| Property / Published In Name String: J. Clin. Invest. / rank | |||
| + | Normal rank | ||
| Property / Volume | |||
| + | 121 | ||
| Property / Volume: 121 / rank | |||
| + | Normal rank | ||
| Property / title | |||
| + | The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors (English) | ||
| Property / title: The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors (English) / rank | |||
| + | Normal rank | ||
| Property / Page(s) | |||
| + | 2723-2735 | ||
| Property / Page(s): 2723-2735 / rank | |||
| + | Normal rank | ||
Latest revision as of 15:38, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Marotta LL, et al. J. Clin. Invest. (2011) cited as Ref 332 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Marotta LL
0 references
2011
0 references
J. Clin. Invest.
0 references
121
0 references
The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors (English)
0 references
2723-2735
0 references
